Gland Pharma · NSE: GLAND · BSE: 543245
Q3 FY24 results · Oct–Dec 2023
Gland Pharma reported revenue from operations of ₹1,545.15 crore (up 64.7% from Q3 FY23) and net profit of ₹191.86 crore (down 17.3% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,545.15 | 938.29 | +64.7% | 1,373.42 | +12.5% |
| Other income | 37.39 | 61.51 | −39.2% | 53.16 | −29.7% |
| Total income | 1,582.55 | 999.80 | +58.3% | 1,426.58 | +10.9% |
| Profit before tax | 283.16 | 310.85 | −8.9% | 289.89 | −2.3% |
| Net profit for the period | 191.86 | 231.95 | −17.3% | 194.08 | −1.1% |
| EPS, basic (₹) | 11.65 | 14.08 | −17.3% | 11.78 | −1.1% |
| Net margin (%) | 12.4 | 24.7 | 14.1 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,097.86 | 925.90 | +18.6% | 1,010.67 | +8.6% |
| Other income | 43.39 | 61.51 | −29.5% | 41.11 | +5.5% |
| Total income | 1,141.25 | 987.41 | +15.6% | 1,051.78 | +8.5% |
| Profit before tax | 371.75 | 305.24 | +21.8% | 347.06 | +7.1% |
| Net profit for the period | 276.81 | 227.54 | +21.7% | 257.53 | +7.5% |
| EPS, basic (₹) | 16.81 | 13.82 | +21.6% | 15.64 | +7.5% |
| Net margin (%) | 25.2 | 24.6 | 25.5 |
Consolidated
- Filed with BSE
- 15 Feb 2024, 11:00 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2024, 11:00 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE